Skip to content

Efinopegdutide

Merck's once-weekly GLP-1/glucagon co-agonist for fatty liver disease, and the first drug in any class to beat semaglutide on a histological MASH endpoint in the same trial. Its phase 2b result, published in The Lancet on 9 November 2026, also produced the clearest example yet of a dose that was too high.

BModerateModerate Data
Last updated 13 citations
TL;DR

Efinopegdutide is a weekly injection that activates two receptors at once: GLP-1, the target of Ozempic, and glucagon, which makes the liver burn its own fat. It is aimed at MASH, the inflamed and scarring form of fatty liver disease. In a 381-person trial published in The Lancet in November 2026, it cleared MASH in 56% to 63% of patients at one year against 13% on placebo — and against 53% for semaglutide 2.4 mg running in the same trial as an open-label comparison. The more interesting finding is what happened to scarring. Fibrosis improved in 52% at the middle 7 mg dose but only 34% at the top 10 mg dose, which was no better than placebo. More drug was worse, and the 10 mg dose also caused more people to quit because of side effects. The company picked 7 mg as the dose with the best balance. The drug has had three owners: Hanmi invented it, Johnson & Johnson ran it in obesity and dropped it, and Merck licensed it in 2020 for liver disease. It is not approved anywhere, and no phase 3 trial has been registered.

What is Efinopegdutide?

Efinopegdutide is a once-weekly injectable peptide that activates both the GLP-1 receptor and the glucagon receptor, under development by Merck for metabolic dysfunction-associated steatohepatitis — MASH, the inflamed and fibrotic form of fatty liver disease formerly called NASH. It is investigational and not approved anywhere. Structurally it is an oxyntomodulin-derived peptide conjugated to the constant region of a human IgG4 antibody through a 10 kDa polyethylene glycol linker. That architecture is Hanmi Pharmaceutical's LAPSCOVERY platform, the same approach used for efpeglenatide, and it is what converts a peptide with a natural half-life measured in minutes into a once-weekly drug. The published characterisation gives a relative receptor potency balance of roughly 2:1 in favour of GLP-1 over glucagon. The reason for adding glucagon agonism to a GLP-1 drug is specific to the liver. GLP-1 receptor agonists reduce liver fat largely by the indirect route of weight loss. Glucagon acts on the hepatocyte directly, stimulating fatty-acid oxidation and suppressing lipogenesis. The bet is that combining the two produces more hepatic effect than weight loss alone can deliver — and efinopegdutide is the only drug in its class that has tested that bet against a GLP-1 comparator in the same trial, twice. The molecule has had three owners. Hanmi developed it as HM12525A. Johnson & Johnson licensed it in 2015 and ran it as JNJ-64565111 in obesity and type 2 diabetes before returning it. Merck licensed it from Hanmi in August 2020 and redirected it to liver disease, where it has stayed since.

What Efinopegdutide Is Investigated For

Efinopegdutide has one serious indication and one abandoned one, and the abandoned one explains a lot about the serious one. MASH is the current programme. The phase 2b trial, published in The Lancet on 9 November 2026, randomised 386 adults with biopsy-confirmed MASH and stage 2 or 3 fibrosis at 176 centres in 26 countries; 381 received at least one dose and were analysed. Patients got efinopegdutide at 4, 7 or 10 mg, placebo, or open-label semaglutide 2.4 mg. At 52 weeks, MASH resolution without worsening of fibrosis — the primary endpoint, with missing biopsies counted as failures — occurred in 56% (31 of 55) at 4 mg, 63% (31 of 49) at 7 mg and 61% (35 of 57) at 10 mg, against 13% (7 of 53) on placebo. Each dose beat placebo by 43 to 50 percentage points with p<0.0001. The semaglutide arm reached 53% (26 of 49). The fibrosis result is where the trial becomes genuinely informative. Improvement of at least one fibrosis stage without worsening steatohepatitis occurred in 43% (32 of 75) at 4 mg, 52% (39 of 75) at 7 mg and 34% (26 of 77) at 10 mg, against 21% (16 of 77) on placebo and 25% (16 of 65) on semaglutide. The 4 mg and 7 mg doses separated clearly from placebo — 21.7 points (p=0.0038) and 30.4 points (p<0.0001) — and the 10 mg dose did not, at 13.0 points with p=0.072. The highest dose, which produced the most weight loss and the most gastrointestinal adverse events, was the one that failed on fibrosis. Discontinuations for adverse events tracked the same way: 11% at 10 mg against 3 to 4% at the lower doses and 1% on placebo. Merck identified 7 mg as the dose with the best benefit-risk profile, and the trial's own interpretation says so. The earlier phase 2a trial had set this up. 145 patients with fatty liver and at least 10% liver fat content were randomised openly to efinopegdutide 10 mg or semaglutide 1 mg for 24 weeks. Liver fat fell 72.7% on efinopegdutide against 42.3% on semaglutide (p<0.001), while weight loss was similar — 8.5% against 7.1%, p=0.085. That dissociation, a large difference in liver fat without a large difference in weight, is the best available evidence that the glucagon arm does something to the liver beyond what weight loss does. The abandoned indication was obesity, under Janssen. A 474-person phase 2 in class II/III obesity produced placebo-subtracted weight loss of 6.8%, 8.1% and 10.0% at 26 weeks, beating open-label liraglutide 3.0 mg at 5.8% — but only 72.4% of participants completed treatment, and nausea and vomiting were markedly more common than on placebo or liraglutide. A companion 195-person trial in type 2 diabetes with obesity was worse: weight fell by 4.6% to 7.2% placebo-subtracted at 12 weeks, but HbA1c did not improve at all, and fasting plasma glucose and fasting insulin rose. That is glucagon agonism showing its other face — the same receptor that drives hepatic fat oxidation also raises hepatic glucose output — and it is why a drug with impressive weight-loss numbers was not pursued in diabetes. No phase 3 trial has been registered. A phase 2 study in compensated cirrhosis due to steatohepatitis completed in August 2026 with liver fat content at week 28 as a primary endpoint, and its results have not been reported.

MASH resolution without worsening fibrosis — 63% at the 7 mg dose versus 13% on placebo at 52 weeks
Moderate70%
Fibrosis improvement of at least one stage — 52% at 7 mg versus 21% on placebo, and versus 25% on semaglutide 2.4 mg
Moderate70%
Liver fat reduction exceeding semaglutide in a head-to-head phase 2a trial (72.7% versus 42.3%)
Moderate70%
Weight loss — tested in obesity under its previous owner, where it reached 10.0% placebo-subtracted at 26 weeks
Moderate70%
Compensated cirrhosis due to steatohepatitis — a completed phase 2 study with results not yet reported
Limited15%

History & Discovery

Efinopegdutide has been licensed three times and redirected twice, and the shape of its development tells you more about the class than any single trial does. It originated at Hanmi Pharmaceutical in South Korea as HM12525A, built on the company's LAPSCOVERY platform — a peptide joined through a PEG linker to an immunoglobulin Fc fragment to extend half-life from minutes to a week. The same platform produced efpeglenatide, Hanmi's GLP-1 agonist, which uses a 3.4 kDa linker where efinopegdutide uses 10 kDa. The parent molecule is oxyntomodulin, the naturally occurring gut hormone that activates both the GLP-1 and glucagon receptors and which has been of interest since the 1980s precisely because it does both. Janssen licensed it in 2015 for a reported $105 million upfront and developed it as JNJ-64565111 in obesity and type 2 diabetes. Two phase 2 trials reported in 2021: a 474-patient obesity study with placebo-subtracted weight loss up to 10.0%, and a 195-patient diabetes study in which HbA1c did not move. Janssen returned the rights to Hanmi. Merck licensed it on 4 August 2020 for $10 million upfront and up to $860 million in milestones plus double-digit royalties, with Hanmi retaining an option to commercialise in Korea. Merck redirected the programme entirely — away from obesity and diabetes, where the glucagon component is a liability, and toward fatty liver disease, where it is the point. The phase 2a trial comparing it against semaglutide on liver fat reported in 2023, and the phase 2b histology trial published in The Lancet on 9 November 2026. The arc is unusual and instructive. A molecule that looked like a mediocre diabetes drug and an awkward obesity drug became a credible liver drug without changing at all. What changed was the recognition that glucagon receptor agonism's hepatic effects — fat oxidation, suppressed lipogenesis — are the same effects that make it inconvenient in diabetes, and that there is a disease in which those effects are what you want.

How It Works

Efinopegdutide pushes two buttons at once. The GLP-1 button is the familiar one — it slows the stomach, reduces appetite and leads to eating less and losing weight. The glucagon button is less familiar and does something different: it tells the liver to burn its own stored fat and to stop making more. Fatty liver disease is a problem of too much fat inside liver cells, so a drug that both reduces the fat arriving and increases the fat being burned should work on the disease from both ends. The trade-off is that glucagon also tells the liver to release sugar, which is why this drug lowers liver fat impressively but does nothing for blood sugar.

Efinopegdutide is an oxyntomodulin-derived peptide conjugated through a 10 kDa PEG linker to the Fc region of a human IgG4 antibody. Oxyntomodulin is the natural template for this class: a gut hormone that activates both the GLP-1 and glucagon receptors, with a circulating half-life of minutes. The Fc conjugation extends that to a once-weekly dosing interval. The published relative potency balance is approximately 2:1 in favour of GLP-1 over glucagon, although the compound was described under its earlier owner as stimulating the two receptors with comparable potency — a reminder that these ratios are assay-dependent and should not be treated as fixed physical constants. The GLP-1 arm does what GLP-1 receptor agonism always does: enhances glucose-dependent insulin secretion, slows gastric emptying, and acts on hypothalamic circuits to reduce food intake. The resulting weight loss reduces liver fat indirectly, which is how semaglutide produces its hepatic effects. The glucagon arm is the differentiator and acts principally on the hepatocyte. Glucagon receptor activation increases hepatic fatty-acid oxidation, suppresses de novo lipogenesis and increases energy expenditure. These are direct effects on the organ that MASH damages, and they operate independently of how much weight a patient loses. The cleanest evidence that the second mechanism contributes something real is the phase 2a trial. Efinopegdutide 10 mg and semaglutide 1 mg produced similar weight loss — 8.5% against 7.1%, p=0.085 — while liver fat content fell 72.7% against 42.3%, p<0.001. A 30-percentage-point difference in liver fat on a 1.4-percentage-point difference in weight is difficult to attribute to weight loss. The same receptor also produces the programme's clearest liability. Glucagon's best-known physiological job is raising blood glucose through hepatic glycogenolysis and gluconeogenesis. In the 195-patient type 2 diabetes trial run under Janssen, no dose reduced HbA1c, and fasting plasma glucose and fasting insulin rose numerically — the glucagon arm cancelling what the GLP-1 arm would otherwise have delivered. The therapeutic window for a GLP-1/glucagon co-agonist is therefore narrower than for a pure GLP-1 drug, and its position depends on the ratio between the two activities. This is the central design problem of the whole class, and different programmes have placed the ratio differently: pemvidutide at roughly 1:1, survodutide more GLP-1-weighted, efinopegdutide at about 2:1. Why the 10 mg dose underperformed on fibrosis while performing well on MASH resolution is unexplained. Plausible contributors include the higher dropout rate producing more missing biopsies scored as failures, and the possibility that glucagon receptor agonism has a genuinely non-monotonic relationship with fibrotic remodelling. Neither has been tested.

Evidence Snapshot

Overall Confidence62%

Human Clinical Evidence

Two substantial randomised trials and a set of supporting studies. The phase 2b trial (NCT05877547) randomised 386 adults with biopsy-confirmed MASH and F2–F3 fibrosis across 176 centres in 26 countries, analysed 381, and reported at 52 weeks: MASH resolution without worsening fibrosis in 56%, 63% and 61% at 4, 7 and 10 mg against 13% on placebo, all p<0.0001, with semaglutide 2.4 mg at 53%; fibrosis improvement in 43%, 52% and 34% against 21% on placebo and 25% on semaglutide, significant at 4 and 7 mg but not at 10 mg (p=0.072). The phase 2a trial (NCT04944992) randomised 145 patients to efinopegdutide 10 mg or semaglutide 1 mg for 24 weeks and found liver fat reduction of 72.7% against 42.3% (p<0.001). Under its previous owner it was tested in 474 patients with obesity and 195 with type 2 diabetes and obesity. A phase 2 in compensated cirrhosis completed in August 2026 with results unreported. No phase 3 trial is registered.

Animal / Preclinical

Preclinical work on this specific molecule is thin in the published literature, because its development history ran through two large pharmaceutical companies that published little of it. The mechanistic case rests instead on a substantial body of work on glucagon receptor agonism in the liver — fatty-acid oxidation, suppression of lipogenesis, increased energy expenditure — and on oxyntomodulin as the natural dual agonist, rather than on animal studies of efinopegdutide itself.

Mechanistic Rationale

Strong, and unusually well supported by human data rather than inference. The rationale for adding glucagon agonism to GLP-1 is that it acts directly on the hepatocyte rather than through weight loss, and the phase 2a trial tested exactly that: against a GLP-1 comparator at similar weight loss, liver fat fell far further. The same mechanism's cost is equally well documented in the diabetes trial, where glucagon agonism erased the glycaemic benefit. What remains inferential is the step from liver fat and histology to clinical outcomes.

Research Gaps & Open Questions

What the current literature has not yet settled about Efinopegdutide:

  • 01No phase 3 trial has been registered, and no clinical-outcome data exist. Whether 52-week histological improvement prevents cirrhosis, liver transplantation or death is the question that matters and the one no MASH drug has yet answered.
  • 02The failure of the 10 mg dose on fibrosis is unexplained. Distinguishing between a true non-monotonic dose-response, an artefact of the higher dropout rate producing biopsies scored as failures, and chance in a trial with roughly 75 patients per fibrosis comparison would require a trial designed for it.
  • 03The compensated cirrhosis phase 2 completed in August 2026 and its results have not been reported. Cirrhosis is where MASH causes deaths, and it is also where GLP-1-based therapy is least well characterised.
  • 04The comparison against semaglutide is suggestive and methodologically weak. Both trials used open-label semaglutide arms, the phase 2a used a 1 mg diabetes dose, and neither was powered for formal superiority testing. A blinded, adequately powered head-to-head on fibrosis has not been done.
  • 05Nothing is known about durability beyond one year or about what happens after discontinuation — no trial has followed patients off treatment.
  • 06The optimal receptor potency ratio for a liver indication is unresolved across the whole class. Efinopegdutide sits at about 2:1 GLP-1 to glucagon, pemvidutide at roughly 1:1, and survodutide more GLP-1-weighted; no study has compared ratios directly, so the choices are empirical rather than principled.
  • 07Lean mass loss during treatment has not been reported for efinopegdutide despite being a prominent concern across the incretin class, and despite the 10 mg dose producing the most weight loss.
  • 08Whether patients who fail to respond to a pure GLP-1 agonist respond to a co-agonist — the most clinically useful positioning question — has never been studied.

Forms & Administration

Efinopegdutide is a subcutaneous injection given once weekly. In the liver trials it was titrated to the target dose over an eight-week period, which matters: the earlier obesity trials under Janssen administered 5.0, 7.4 or 10.0 mg with no dose escalation at all, and their tolerability was correspondingly poor, with a 27.6% discontinuation rate over 26 weeks. The doses studied in MASH were 4 mg, 7 mg and 10 mg weekly. The developers identified 7 mg as having the best benefit-risk profile, based on its fibrosis result and its discontinuation rate relative to 10 mg. No oral or alternative formulation exists. The molecule is a PEGylated peptide-Fc conjugate produced as a biologic, and it is not something that can be synthesised by a peptide supplier or compounded.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Typical Range

4 mg, 7 mg or 10 mg subcutaneously once weekly in the phase 2b MASH trial; 7 mg was identified by the investigators as the dose with the best benefit-risk profile

Frequency

Once weekly, with titration to the target dose over approximately eight weeks

Timing Considerations

No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.

Protocol Notes

Dosing here is reported from trials, not from any approved label — efinopegdutide is investigational and no regulator has set a dose for it. The dose-response pattern is the single most useful thing a reader can take from this drug's data, because it runs against intuition. Across the three doses tested in MASH, the highest dose was not the best. MASH resolution was broadly flat across 4, 7 and 10 mg (56%, 63%, 61%), but fibrosis improvement peaked at the middle dose: 43%, 52% and 34%, with the 10 mg result failing to separate from placebo at p=0.072. Tolerability moved the other way, with discontinuation for adverse events at 11% on 10 mg against 3 to 4% at the lower doses. The trial's own interpretation nominates 7 mg. Titration matters and the development history demonstrates it. The obesity trials run under Janssen administered 5.0, 7.4 or 10.0 mg with no escalation at all, and 27.6% of participants discontinued over 26 weeks with nausea and vomiting far above placebo. The liver trials titrated over eight weeks and reported discontinuation rates of 1 to 11% over 52 weeks. Nothing about the molecule changed between those programmes. Any dose above 7 mg appears to buy more gastrointestinal toxicity and more weight loss without buying more antifibrotic effect — which in a disease defined by fibrosis is the wrong trade.

Efinopegdutide is not approved for any indication by any regulator and is not lawfully available outside a clinical trial. The doses above are from published phase 2 research and are reported for completeness, not as guidance. Approved therapies for MASH exist, including resmetirom and semaglutide, and are the relevant conversation to have with a hepatologist.

Timeline of Effects

Onset

Gastrointestinal effects appear within the first weeks and are the reason the liver trials titrated over eight weeks rather than starting at the target dose. Liver fat falls quickly: the phase 2a trial measured a 72.7% relative reduction at 24 weeks, and the broader literature on GLP-1-based therapy shows hepatic fat beginning to fall within the first month or two. Weight loss follows the usual GLP-1 trajectory, accumulating over months.

Peak Effect

The histological endpoints were measured at 52 weeks, and that is the only timepoint at which MASH resolution and fibrosis change have been assessed for this drug. Whether the effect was still growing at one year, had plateaued, or had begun to regress is not known, because no trial has biopsied later than that.

After Discontinuation

Entirely unstudied for this molecule. No trial has followed patients after stopping, and there is no off-treatment extension in the published record. What is known from the wider GLP-1 literature — that weight regain is typical after discontinuation, and that liver fat tracks weight — suggests hepatic benefits would be unlikely to persist without continued treatment, but that is inference from a related class rather than data on this drug.

Common Questions

Is efinopegdutide better than semaglutide for fatty liver?

On the endpoints measured, at the doses compared, it looks better for fibrosis and similar for MASH resolution. In the phase 2b trial semaglutide 2.4 mg ran as an open-label reference arm and achieved MASH resolution in 53% against 56–63% across the efinopegdutide doses — a difference too small to call. On fibrosis improvement, the 7 mg efinopegdutide dose reached 52% against semaglutide's 25%, which is a substantial gap. The earlier phase 2a trial compared efinopegdutide 10 mg against semaglutide 1 mg and found liver fat fell 72.7% against 42.3%. Three honest qualifications: the semaglutide arms were open-label rather than blinded, which is a real design weakness; semaglutide 1 mg in the phase 2a trial is a diabetes dose, not the 2.4 mg obesity dose; and neither trial was designed or powered as a formal superiority comparison against semaglutide, so these are descriptive differences, not statistical verdicts.

Why did the highest dose do worse on fibrosis?

Nobody knows, and that is the honest answer. The 10 mg dose produced strong MASH resolution (61%) and more weight loss, but fibrosis improvement at 34% was not significantly better than placebo's 21%, while the 7 mg dose reached 52%. Several explanations are plausible and none is established: a dose that drives too much weight loss too fast may itself stress the liver; the higher rate of gastrointestinal adverse events and 11% discontinuation at 10 mg means more patients with incomplete exposure and more missing biopsies, which the primary analysis counted as failures; or glucagon receptor agonism may have a therapeutic window in the liver where more is genuinely not better. What can be said is that it is not an isolated oddity — the same non-monotonic pattern has shown up repeatedly in this drug class, and it is the reason dose selection for MASH is not simply a matter of pushing to the maximum tolerated dose.

Is efinopegdutide a weight-loss drug?

It was, and it is not being developed as one. Under Janssen it produced placebo-subtracted weight loss of 10.0% at 26 weeks in people with class II/III obesity — comparable to the better GLP-1 drugs — and that programme was dropped. The companion diabetes trial shows why the picture is more complicated than the weight number suggests: HbA1c did not improve, and fasting glucose and insulin rose, because glucagon receptor agonism increases hepatic glucose output even as it drives fat oxidation. Merck's programme is a liver programme, and the weight loss in it is a mechanism and a side-effect, not the goal. It is not available for weight loss and is not being studied for it.

What stage of development is it at?

Phase 2, with no phase 3 registered. That is worth stating precisely because secondary coverage sometimes describes it as a phase 3 asset. As of 18 November 2026, ClinicalTrials.gov lists seven efinopegdutide studies — five phase 2 and two phase 1 — and all of them are complete. The phase 2b MASH trial reported in The Lancet on 9 November 2026 and the compensated cirrhosis phase 2 completed in August 2026 with results unreported. A MASH phase 3 would need to run for years on histological and then clinical-outcome endpoints, so even a decision to proceed would put approval well into the next decade.

What does adding glucagon to a GLP-1 drug actually do?

It adds a direct effect on the liver cell. A GLP-1 receptor agonist reduces liver fat mostly as a downstream consequence of eating less and weighing less. Glucagon receptors are abundant on hepatocytes, and activating them stimulates fatty-acid oxidation and suppresses new fat synthesis in the liver itself, as well as increasing energy expenditure. The phase 2a trial is the cleanest demonstration that this is more than theory: against semaglutide, efinopegdutide produced far greater liver fat reduction (72.7% versus 42.3%) with only a modest and non-significant difference in weight loss. The cost of the same mechanism is visible in the diabetes data, where glucagon agonism raised hepatic glucose output enough to erase any HbA1c benefit.

Can I get efinopegdutide?

No. It is investigational, approved by no regulator, and every registered trial is now complete, so there is not currently an enrolment route either. It is a PEGylated peptide-Fc conjugate manufactured as a biologic, which puts it outside what compounding pharmacies or research-chemical suppliers can produce — anything sold under this name should be assumed not to be it. The approved drugs for MASH are a different question: resmetirom (Rezdiffra) was approved by the FDA in March 2024, and semaglutide 2.4 mg received accelerated approval on 15 August 2025 for non-cirrhotic MASH with stage 2 to 3 fibrosis, so a patient with the condition has options that exist.

Who Efinopegdutide Is NOT For

Contraindications
  • •Not applicable as a clinical contraindication list in the usual sense, because the drug is unapproved and has no label — what follows is derived from trial exclusion criteria and from the known behaviour of the class
  • •Type 2 diabetes managed with the expectation of glycaemic benefit — this drug did not lower HbA1c at any dose in a dedicated 195-patient trial, and fasting glucose rose
  • •Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, the standard class exclusion for GLP-1 receptor agonists
  • •History of pancreatitis, also a standard class exclusion
  • •Decompensated cirrhosis — the cirrhosis study enrolled compensated patients only, and nothing is known beyond that
  • •Pregnancy and breastfeeding — no data in either setting
  • •Severe gastrointestinal disease or gastroparesis, given that gastrointestinal adverse events were the dominant toxicity at every dose

Drug & Supplement Interactions

No formal drug-interaction studies have been published for efinopegdutide specifically, and no label exists to summarise. What can be said comes from mechanism and from the class. The interaction with the greatest practical significance is with glucose-lowering therapy, and it runs in an unusual direction. A GLP-1 receptor agonist would ordinarily raise the risk of hypoglycaemia when combined with insulin or a sulfonylurea, prompting a dose reduction. Efinopegdutide's glucagon component increases hepatic glucose output, and in the dedicated type 2 diabetes trial the net effect on HbA1c was nil while fasting glucose rose. The practical implication is that neither the usual assumption nor its opposite can be relied on, and that anyone combining this drug with glycaemic therapy in a trial setting would need to monitor rather than predict. Delayed gastric emptying is a class effect and can alter the absorption of oral medications taken at the same time, which matters most for drugs with narrow therapeutic windows or time-sensitive absorption. The effect on oral contraceptive absorption has been studied for other GLP-1 drugs and not for this one. There is no cytochrome P450 interaction profile to describe. As a PEGylated peptide-Fc conjugate it is cleared by proteolysis and receptor-mediated mechanisms rather than hepatic oxidative metabolism, so the classic enzyme-inhibition and induction interactions do not apply. Combination with another GLP-1 receptor agonist has no rationale and was not studied; the phase 2b trial ran semaglutide as a separate arm, not a combination.

Safety Profile

Safety Information

Common Side Effects

Gastrointestinal events were the most frequently reported adverse events in the phase 2b trial, with the highest rates at the 10 mg dose — the standard profile for this classNausea and vomiting were notably more common than on placebo or liraglutide in the earlier obesity trials under Janssen, at doses of 5.0 to 10.0 mg given without dose escalationDiscontinuation for adverse events in the phase 2b trial: 11% (9 of 79) at 10 mg, 3–4% at 4 and 7 mg, and 1% on placeboMerck characterised the overall safety profile in the phase 2b trial as broadly consistent with semaglutide's

Cautions

  • • Investigational — not approved by the FDA, the EMA or any other regulator for any indication
  • • The 10 mg dose was both the least effective on fibrosis and the worst tolerated; the developers selected 7 mg as the best benefit-risk dose, and higher is not better with this drug
  • • Glucagon receptor agonism raises hepatic glucose output. In the type 2 diabetes trial, HbA1c did not fall at any dose and fasting plasma glucose and fasting insulin rose numerically — this is not a glucose-lowering drug despite being a GLP-1 agonist
  • • The obesity trials under Janssen had a 27.6% discontinuation rate over 26 weeks, which is high and was driven by tolerability; those trials used no dose escalation, which the later liver trials did
  • • Everything known about the drug comes from phase 1 and 2 studies in selected trial populations; there is no long-term safety database

What We Don't Know

The most consequential unknown is whether histological improvement at 52 weeks translates into fewer cirrhosis diagnoses, liver transplants and deaths. No MASH drug has yet been shown to do that, and the surrogate endpoints used in phase 2b — MASH resolution and fibrosis stage on biopsy — are accepted by regulators as reasonably likely to predict benefit rather than demonstrated to deliver it. Beyond that: the compensated cirrhosis phase 2 completed in August 2026 and its results have not been reported; durability beyond one year is untested; nothing is known about what happens on discontinuation; the reason the 10 mg dose underperformed on fibrosis is unexplained; and whether the drug's apparent advantage over semaglutide on fibrosis survives a blinded, adequately powered head-to-head comparison is simply unknown, because no such trial has been run.

Myths & Misconceptions

Myth

Efinopegdutide is in phase 3 trials for MASH.

Reality

It is not, and this error appears often enough in secondary coverage to be worth correcting. As of 18 November 2026, ClinicalTrials.gov lists seven efinopegdutide studies — five phase 2 and two phase 1 — and all are complete. The compensated cirrhosis study that is sometimes described as phase 3 is registered as phase 2 with 85 participants. No phase 3 trial of efinopegdutide exists in any indication.

Myth

It beat semaglutide, so it is the better drug.

Reality

It produced better numbers than semaglutide on fibrosis in two trials, which is genuinely notable and is the main reason to be interested in it. But both semaglutide arms were open-label rather than blinded; the phase 2a trial used semaglutide 1 mg, a diabetes dose, rather than the 2.4 mg obesity dose; and neither trial was designed or powered as a superiority comparison. On MASH resolution the difference was small — 53% for semaglutide against 56–63%. Semaglutide, meanwhile, is approved and available, and efinopegdutide is neither.

Myth

Higher doses of a MASH drug work better.

Reality

This drug is a direct counterexample. The 10 mg dose produced more weight loss and more gastrointestinal adverse events than 7 mg, and worse fibrosis improvement — 34% against 52%, failing to separate from placebo at p=0.072. The investigators selected 7 mg as the best benefit-risk dose on exactly that basis. The pattern is not unique to efinopegdutide: non-monotonic dose-response on fibrosis has appeared repeatedly in this class, which is why MASH dose selection is not a matter of finding the maximum tolerated dose.

Myth

Adding glucagon to a GLP-1 drug is strictly better.

Reality

It is a trade, and this molecule's own history shows both sides of it. Glucagon receptor agonism adds direct hepatic fat oxidation — the phase 2a trial showed a 30-point greater liver fat reduction than semaglutide at nearly identical weight loss. The same receptor raises hepatic glucose output, and in the 195-patient type 2 diabetes trial HbA1c did not fall at any dose while fasting glucose and insulin rose. A drug that works on the liver because of glucagon is, for the same reason, not a glucose-lowering drug.

Myth

MASH resolution on biopsy means the disease is cured.

Reality

It means that at a single timepoint, a pathologist reading a needle sample judged the defining features of steatohepatitis to have gone, without fibrosis having worsened. It is a regulator-accepted surrogate — reasonably likely to predict clinical benefit — and not a demonstrated reduction in cirrhosis, transplantation or death. It is also measured on a small piece of a large and unevenly affected organ, and sampling variability on liver biopsy is well documented. The endpoint is the best available; it is not an outcome.

Published Research

13 studies

Efficacy and safety of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage 2-3 fibrosis: a phase 2b, randomised, placebo-controlled study.

Lawitz, Wong, Shankar, Francque, Patel and colleagues, The Lancet, 9 November 2026 — the defining trial for this drug and the source of every phase 2b figure on this page. 1704 screened, 386 randomised 1:1:1:1:1, 381 dosed and analysed, at 176 centres in 26 countries, all with biopsy-confirmed MASH and F2 (63%) or F3 (37%) fibrosis. Missing end-of-treatment biopsies counted as failures. MASH resolution without worsening fibrosis at 52 weeks: 56% (4 mg), 63% (7 mg), 61% (10 mg) versus 13% on placebo, all p<0.0001; open-label semaglutide 2.4 mg reached 53%. Fibrosis improvement of at least one stage: 43%, 52%, 34% versus 21% on placebo and 25% on semaglutide — significant at 4 mg (p=0.0038) and 7 mg (p<0.0001) but not at 10 mg (p=0.072). Discontinuation for adverse events was 11% at 10 mg against 3–4% at lower doses and 1% on placebo. The authors nominate 7 mg as the best benefit-risk dose. Funded by Merck Sharp & Dohme.

Clinical TrialPMID: 43003105

Efinopegdutide: a step towards precision in MASH therapy?

ReviewPMID: 43003104

Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.

Meta-AnalysisPMID: 42811393

Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes: An Updated Systematic Review.

ReviewPMID: 42673585

Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.

Meta-AnalysisPMID: 40489581

Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis.

Meta-AnalysisPMID: 39028914

A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.

Romero-Gomez, Lawitz, Shankar and colleagues, Journal of Hepatology, October 2023 — the trial that made the case for the glucagon arm doing something weight loss does not. 145 patients with at least 10% liver fat content were randomised 1:1 to efinopegdutide 10 mg or semaglutide 1 mg weekly for 24 weeks, open-label, stratified by type 2 diabetes status. Liver fat content fell 72.7% (90% CI 66.8–78.7) on efinopegdutide against 42.3% (36.5–48.1) on semaglutide, p<0.001, while weight loss differed by only 8.5% against 7.1% (p=0.085). That dissociation — a 30-point difference in liver fat on a 1.4-point difference in weight — is the strongest available evidence that hepatic glucagon receptor agonism contributes directly rather than through weight. Note the 90% confidence intervals and the open-label design, and that semaglutide 1 mg is a diabetes dose rather than the 2.4 mg used for obesity.

Clinical TrialPMID: 37355043

Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study.

Alba, Yee, Frustaci and colleagues, Clinical Obesity, April 2021 — the obesity programme that was not continued, and useful for calibrating what the molecule can do outside the liver. 474 adults with a BMI of 35 to 50 and no diabetes were randomised to placebo, efinopegdutide at 5.0, 7.4 or 10.0 mg without dose escalation, or open-label liraglutide 3.0 mg. Placebo-subtracted weight loss at 26 weeks was 6.8%, 8.1% and 10.0% against liraglutide's 5.8%. The catch is in the completion rate: only 72.4% finished treatment, and nausea and vomiting were markedly more common than on placebo or liraglutide. Administering the full dose without titration is the most likely explanation, and the later liver trials titrated over eight weeks.

Clinical TrialPMID: 33475255

Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose-ranging study.

Di Prospero, Yee, Frustaci and colleagues, Clinical Obesity, April 2021 — the trial that explains why this molecule is not a diabetes drug, and the one most often missing from accounts of it. 195 patients with type 2 diabetes and class II/III obesity received placebo or 5.0, 7.4 or 10.0 mg weekly for 12 weeks. Placebo-subtracted weight loss was 4.6%, 5.9% and 7.2% — respectable numbers. But HbA1c did not fall at any dose, fasting insulin rose slightly and fasting plasma glucose rose numerically at the two lower doses. Glucagon receptor agonism increases hepatic glucose output, and here it cancelled what the GLP-1 component would have delivered. The same mechanism that makes the drug work on liver fat is the reason it does nothing for glycaemia.

Clinical TrialPMID: 33475251

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

Clinical Trial Registry

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

The registry record for the cirrhosis study, worth citing because it is frequently described in secondary coverage as a phase 3 trial. It is phase 2, enrolled 85 participants, ran from July 2024 to 3 August 2026, and has liver fat content at week 28 plus adverse-event and discontinuation rates as its primary endpoints. No results have been reported. As of 18 November 2026 no phase 3 trial of efinopegdutide is registered on ClinicalTrials.gov in any indication.

Clinical Trial Registry

Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis

Company Announcement

A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)

Clinical Trial Registry

Efinopegdutide Compared

Quick Facts

Class
GLP-1 / Glucagon Receptor Co-agonist
Tier
B
Evidence
Moderate
Safety
Moderate Data
Updated
Nov 2026
Citations
13PubMed

Also known as

MK-6024HM12525AJNJ-64565111LAPS-GLP/GCG

Tags

GLP-1GlucagonDual AgonistMASHLiverWeight LossInvestigational

Conditions Discussed

Evidence Score

Overall Confidence62%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.